is tirzepatide hard on kidneys death rate linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s Tirzepatide after intensive lifestyle intervention – Cardio-kidney-metabolic protective effects of semaglutide

Program highlight: The session Obstructive Sleep Apnea and Cardiovascular Disease VSSMVNHA Consensus, which aims to promote interdisciplinary collaboration between Cardiology, Pulmonology, and Sleep Medicine in the screening, diagnosis, and management of sleep apnea in cardiovascular patients

were responsible for discussing the manuscript and making critical logical and grammar revisions

Other potential concerns with long-term GLP-1 agonist use include gallbladder disease (cholelithiasis, cholecystitis), pancreatitis, and potential effects on thyroid C-cells

Experts note that new-onset constipation usually appears within the first 4-16 weeks of GLP-1 therapy, often in the first month